DNA damage response gene alterations are now attracting increasing attention for the positive correlation with elevated TMB and improved clinical outcomes of programmed death 1 (PD-1)/programmed death 1 ligand (PD-L1) axis inhibition in various cancers (23, 24). This evidence concerns the gene CD274 and cancer.